Biosimilar threat starts to creep up on Roche as Rituxan loses ground
admin 19th October 2017 Uncategorised 0Roche was able to turn in 6% growth in the third quarter, partly thanks to its new multiple sclerosis med Ocrevus, but performance from its aging—and best-selling—cancer meds highlighted problems ahead.
More: Biosimilar threat starts to creep up on Roche as Rituxan loses ground
Source: fierce